CABA
Cabaletta Bio, Inc.
16.02
USD
This page is just a preview of the data found in TrendSpider’s full version
Cabaletta Bio, Inc. stock is up 3.09% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 12 Oct 17:31 | 15 Dec, 2023 | 15.00 | 0 | ||
| 13 Nov 20:00 | 17 May, 2024 | 15.00 | 180 | ||
| 14 Nov 17:44 | 17 May, 2024 | 15.00 | 788 | ||
| 15 Nov 15:43 | 17 May, 2024 | 2.50 | 100 | ||
| 20 Nov 14:47 | 17 May, 2024 | 15.00 | 1746 | ||
| 22 Nov 18:58 | 17 May, 2024 | 2.50 | 100 | ||
| 28 Nov 16:44 | 15 Dec, 2023 | 12.50 | 1051 | ||
| 28 Nov 16:53 | 15 Dec, 2023 | 7.50 | 10 | ||
| 28 Nov 16:58 | 15 Dec, 2023 | 15.00 | 5011 | ||
| 29 Nov 15:54 | 15 Dec, 2023 | 15.00 | 4030 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
